Stockscreener 앱 받기
3.73
10.12%
-0.42
시장 영업 전:
3.78
0.05
+1.34%
Cabaletta Bio Inc 주식(CABA)의 최신 뉴스
Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN
Number of shareholders of Cabaletta Bio, Inc. – NASDAQ:CABA - TradingView
Number of shareholders of Cabaletta Bio, Inc. – BMV:CABA - TradingView
Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
CABA Stock Pops As $30 Target, Funding And Manufacturing Align - timothysykes.com
Cabaletta, Cellares Sign Manufacturing Deal for Rese-Cel Supply - MyChesCo
Cabaletta Bio prices $150 million public offering - The Pharma Letter
Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial - Stocktwits
Cabaletta Bio to Present Rese-Cel Data at ASGCT 2026 Meeting - MyChesCo
Cabaletta Bio | 8-K: Current report - Moomoo
Cabaletta Bio Stock Jumps: Inside the $150 Million Bet on CABA’s Cell Therapy - TechStock²
CABA Reiterates by Cantor Fitzgerald -- Price Target Maintained at $30 - GuruFocus
Cabaletta Bio, Inc. Files Form 8-K with SEC – Company Information, Stock Details, and Compliance Disclosure - Minichart
Cabaletta Bio (CABA) Reports Progress in Pemphigus Vulgaris Trea - GuruFocus
Cabaletta Bio Shares Rise After $150M Underwritten Offering Prices - Moomoo
Guggenheim reiterates Cabaletta Bio stock rating on trial data By Investing.com - Investing.com South Africa
Guggenheim reiterates Cabaletta Bio stock rating on trial data - Investing.com
Global Business Travel Group Posts Upbeat Q1 Results, Joins Cabaletta Bio, Aura Biosciences And Other Big - Benzinga
Cabaletta Bio prices $150 million stock offering at $2.90 - Investing.com UK
Cabaletta Bio prices $150 million stock offering at $2.90 By Investing.com - Investing.com South Africa
Cabaletta Bio Prices $150 Million Stock Offering - Moomoo
Cabaletta Bio stock jumps on $150M offering pricing - Investing.com
Cabaletta Bio stock jumps on $150M offering pricing By Investing.com - Investing.com South Africa
Cabaletta Bio prices $150M stock offering - MSN
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering - The Manila Times
Cabaletta Bio Announces $150 Million Equity Offering - TipRanks
Cabaletta Bio (NASDAQ: CABA) raises $150M via 51.7M-share offering - Stock Titan
Cabaletta Bio (NASDAQ: CABA) prices $150M equity raise to fund rese-cel - Stock Titan
Backed by Eli Lilly, Cabaletta sells $150M in new shares - Stock Titan
Cabaletta Bio (NASDAQ: CABA) to share new rese-cel RESET-PV data at ASGCT 2026 - Stock Titan
Cabaletta Bio, Inc. $CABA Shares Bought by Jennison Associates LLC - MarketBeat
CABA News | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill
Stock Traders Buy High Volume of Call Options on Cabaletta Bio (NASDAQ:CABA) - MarketBeat
H.C. Wainwright reiterates Cabaletta Bio stock rating on manufacturing scalability - Investing.com Australia
Cabaletta Bio enters agreement with California company to manufacture one of its cell therapies - Pennsylvania Business Report -
H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com UK
Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace
Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com South Africa
CABA Forms Agreement with Cellares for Cost-Effective Cell Thera - GuruFocus
CABA Gains Strategic Partnership for Efficient Rese-Cel Producti - GuruFocus
Cabaletta Bio | DEF 14A: Definitive information statements - Moomoo
Cabaletta Bio signs 10-year manufacturing deal with Cellares - Investing.com
1.77%
0.25%
자본화:
|
볼륨(24시간):